Angel Augusto Rodriguez, MD

Assistant Professor of Clinical Medicine, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Dr. Angel Augusto Rodriguez is board certified by the American Board of Internal Medicine in Medical Oncology.  He leads the Triple Negative Breast Cancer Program at Houston Methodist Cancer Center.  Dr. Rodriguez directs the Denver Harbor Clinic, which provides breast cancer screening and treatment for underinsured patients.  

Description of Research

Dr. Rodriguez is active in breast oncology research and clinical trials.

Areas Of Expertise

Triple negative breast cancer Breast cancer
Education & Training

Clinical Fellowship , Baylor College of Medicine
Residency , Baylor College of Medicine
MD , Universidad Central Del Caribe Excuela De Medicina

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Bear, HD, Wan, W, Robidoux, A, Rubin, P, Limentani, S, White, RL, Granfortuna, J, Hopkins, JO, Oldham, D, Rodriguez, A & Sing, AP 2017, Journal of Surgical Oncology. DOI:

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
Tanei, T, Choi, DS, Rodriguez, AA, Liang, DH, Dobrolecki, L, Ghosh, M, Landis, MD & Chang, JC 2016, Breast Cancer Research, vol 18, no. 1, 6. DOI:

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Liang, DH, Ensor, JE, Liu, ZB, Patel, A, Patel, TA, Chang, JC & Rodriguez, AA 2016, Breast Cancer Research and Treatment, vol 155, no. 1, pp. 139-149. DOI:

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods
Patel, TA, Puppala, M, Ogunti, RO, Ensor, Jr. JE, He, T, Shewale, JB, Ankerst, DP, Kaklamani, VG, Rodriguez, AA, Wong, STC & Chang, JC 2016, Cancer. DOI:

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
Granados-Principal, S, Liu, Y, Guevara, ML, Blanco, E, Choi, DS, Qian, W, Patel, T, Rodriguez, AA, Cusimano, J, Weiss, HL, Zhao, H, Landis, MD, Dave, B, Gross, SS & Chang, JC 2015, Breast Cancer Research, vol 17, no. 1, 25. DOI:

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer
Niravath, P, Tham, YL, Wang, T, Rodriguez, A, Foreman, C, Hilsenbeck, SG, Elledge, R & Rimawi, M 2015, Oncologist, vol 20, no. 1. DOI:

Erratum: Dual HER2 blockade: Preclinical and clinical data
Patel, TA, Dave, B, Rodriguez, AA, Chang, JC, Perez, EA & Colon-Otero, G 2014, Breast Cancer Research. DOI:

Dual HER2 blockade: Preclinical and clinical data
Patel, TA, Dave, B, Rodriguez, AA, Chang, JC, Perez, EA & Colon-Otero, G 2014, Breast Cancer Research, vol 16, no. 4, 419. DOI:

Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast
Chen, AC, Paulino, AC, Schwartz, MR, Rodriguez, AA, Bass, BL, Chang, JC & Teh, BS 2014, British Journal of Cancer, vol 111, no. 3, pp. 619-622. DOI:

Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1
Choi, DS, Blanco, E, Kim, YS, Rodriguez, AA, Zhao, H, Huang, THM, Chen, CL, Jin, G, Landis, MD, Burey, LA, Qian, W, Granados, SM, Dave, B, Wong, HH, Ferrari, M, Wong, STC & Chang, JC 2014, Stem Cells, vol 32, no. 9, pp. 2309-2323. DOI:

Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases
Zhao, H, Jin, G, Cui, K, Ren, D, Liu, T, Chen, P, Wong, S, Li, F, Fan, Y, Rodriguez, A, Chang, J & Wong, STC 2013, Cancer Research, vol 73, no. 20, pp. 6149-6163. DOI:

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer
Yu, KD, Zhu, R, Zhan, M, Rodriguez, AA, Yang, W, Wong, S, Makris, A, Lehmann, BD, Chen, X, Mayer, I, Pietenpol, JA, Shao, ZM, Symmans, WF & Chang, JC 2013, Clinical Cancer Research, vol 19, no. 10, pp. 2723-2733. DOI:

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Rimawi, MF, Mayer, IA, Forero, A, Nanda, R, Goetz, MP, Rodriguez, AA, Pavlick, AC, Wang, T, Hilsenbeck, SG, Gutierrez, C, Schiff, R, Osborne, CK & Chang, JC 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 31, no. 14, pp. 1726-1731. DOI:

Prognostic markers for invasive micropapillary carcinoma of the breast: A population-based analysis
Chen, AC, Paulino, AC, Schwartz, MR, Rodriguez, AA, Bass, BL, Chang, JC & Teh, BS 2013, Clinical Breast Cancer, vol 13, no. 2, pp. 133-139. DOI:

A gene transcription signature of obesity in breast cancer
Creighton, CJ, Sada, YH, Zhang, Y, Tsimelzon, A, Wong, H, Dave, B, Landis, MD, Bear, HD, Rodriguez, A & Chang, JC 2012, Breast Cancer Research and Treatment, vol 132, no. 3, pp. 993-1000. DOI:

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: An in vivo analysis in triple-negative breast cancer models
Zhao, H , Cui, K, Nie, F, Wang, L, Brandl, MB, Jin, G, Li, F, Mao, Y, Xue, Z, Rodriguez, A, Chang, J & Wong, STC 2012, Breast Cancer Research and Treatment, vol 131, no. 2, pp. 425-436. DOI:

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
Rodriguez, AA, Makris, A, Wu, MF, Rimawi, M, Froehlich, A, Dave, B, Hilsenbeck, SG, Chamness, GC, Lewis, MT, Dobrolecki, LE, Jain, D, Sahoo, S, Osborne, CK & Chang, JC 2010, Breast Cancer Research and Treatment, vol 123, no. 1, pp. 189-196. DOI:

Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
Debeb, BG, Zhang, X, Krishnamurthy, S, Gao, H, Cohen, E, Li, L, Rodriguez, AA, Landis, MD, Lucci, A, Ueno, NT, Robertson, F, Xu, W, Lacerda, L, Buchholz, TA, Cristofanilli, M, Reuben, JM, Lewis, MT & Woodward, WA 2010, Molecular Cancer, vol 9, 180. DOI:

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Creighton, CJ, Li, X, Landis, M, Dixon, JM, Neumeister, VM, Sjolund, A, Rimm, DL, Wong, H, Rodriguez, A, Herschkowitz, JI, Fan, C, Zhang, X, He, X, Pavlick, A, Gutierrez, MC, Renshaw, L, Larionov, AA, Faratian, D, Hilsenbeck, SG, Perou, CM, Lewis, MT, Rosen, JM & Chang, JC 2009, Proceedings of the National Academy of Sciences of the United States of America, vol 106, no. 33, pp. 13820-13825. DOI: